GABBIANI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.054
EU - Europa 3.183
AS - Asia 463
AF - Africa 11
SA - Sud America 3
OC - Oceania 1
Totale 7.715
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.050
PL - Polonia 1.188
RU - Federazione Russa 789
SE - Svezia 408
IE - Irlanda 246
IT - Italia 175
SG - Singapore 167
DE - Germania 110
HK - Hong Kong 109
UA - Ucraina 108
CN - Cina 73
FI - Finlandia 61
GB - Regno Unito 45
IN - India 45
TR - Turchia 32
VN - Vietnam 20
JO - Giordania 13
BE - Belgio 12
ES - Italia 11
FR - Francia 11
CI - Costa d'Avorio 7
AT - Austria 6
NL - Olanda 6
CH - Svizzera 5
CA - Canada 4
SC - Seychelles 4
BR - Brasile 3
IR - Iran 2
AM - Armenia 1
AU - Australia 1
JP - Giappone 1
PT - Portogallo 1
RO - Romania 1
Totale 7.715
Salva come PNG Salva come JPEG
Città #
Warsaw 1.186
Santa Clara 688
Fairfield 505
Chandler 330
Dublin 246
Ashburn 233
Woodbridge 230
Houston 210
Seattle 210
Cambridge 208
Jacksonville 181
Wilmington 180
Singapore 139
Ann Arbor 113
Princeton 62
Hong Kong 58
Boardman 51
Buffalo 48
Altamura 46
Lawrence 45
Boston 40
Kent 38
Mumbai 35
Beijing 33
Medford 32
San Diego 32
Florence 31
Izmir 27
Shanghai 23
Falls Church 21
Dong Ket 16
Moscow 15
Norwalk 15
New York 14
Brussels 12
Hillsboro 12
Andover 10
Milan 9
Auburn Hills 8
Pisa 8
West Jordan 8
Abidjan 7
Arezzo 7
Verona 7
Yubileyny 7
Falkenstein 6
Vienna 6
Bern 5
Bremen 5
Frankfurt Am Main 5
Helsinki 5
Livorno 5
Phoenix 5
Barcelona 4
London 4
Rome 4
La Laguna 3
Los Angeles 3
Madrid 3
New Delhi 3
Toronto 3
Camerino 2
Casarza Ligure 2
Düsseldorf 2
Laurel 2
Paris 2
Radom 2
Serra 2
Taua 2
Togliatti 2
Acton 1
Adiyaman 1
Amsterdam 1
Augusta 1
Bari 1
Bochum 1
Caserta 1
Central 1
Chennai 1
Chicago 1
Dallas 1
Fossalunga 1
Fremont 1
Genova 1
Grevenbroich 1
Groningen 1
Guangzhou 1
Gunzenhausen 1
Hanover 1
Hefei 1
Henderson 1
Huzhou 1
Hyderabad 1
Islington 1
Montréal 1
Munich 1
Napoli 1
Padova 1
Palermo 1
Pittsburgh 1
Totale 5.553
Salva come PNG Salva come JPEG
Nome #
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 290
MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS 279
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 278
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 273
Proteomic and metallomic strategies for understanding the mode of action of anticancer metallodrugs. 239
Unravelling the Chemical Nature of Copper Cuprizone 201
Exploring metal complexes-protein/peptide interactions by high resolution mass spectrometry 188
Mass spectrometry and metallomics: stability and binding site location in the Cyt c-CDDP model system 186
Mass Spectrometry and Metallomics: binding site location in the Cyt c-CDDP model system 186
Exploring the interactions between phosphane-based platinum(II) dichlorides and cytochrome c by electrospray ionization high resolution mass spectrometry 176
Exploring the interactions of a “rule-breaker” iodo-platinum(II) complex with cytochrome c by mass spectrometry 176
Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. 158
Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. 143
Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. 137
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 136
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 135
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme 133
The copper(II) coordination abilities of three novel cyclic tetrapeptides with -His-Xaa-His- motif 130
Trans-cis-cis-[RuCl(2)(DMSO)(2)(2-amino-5-methyl-thiazole)(2)], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. 127
Structural characterization, solution studies, and dft calculations on a series of binuclear gold(iii) oxo complexes: relationships to biological properties 125
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 123
Trace Copper(II) or Zinc(II) Ions Drastically Modify the Aggregation Behavior of Amyloid-beta(1-42): An AFM Study 119
Exploiting soft and hard x-ray absorption spectroscopy to characterize metallodrug/protein interactions: the binding of [trans-rucl4(im)(dimethylsulfoxide)][imH] (im = imidazole) to bovine serum albumin 118
The copper(II) binding properties of the cyclic peptide c(HGHK) 115
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. 115
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 112
The C2 variant of human serum transferrin retains the iron binding properties of the native protein 111
Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c. 109
Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c 107
The X-ray Structure of the Adduct between NAMI-A and CarbonicAnhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins 106
The reaction of artemisinins with hemoglobin: A unified picture 105
Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands 105
Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from x-ray diffraction and mass spectrometry studies. 103
DOTAP/DOPE and DC-Chol/DOPE lipoplexes for gene delivery studied by circular dichroism and other biophysical techniques 102
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 100
null 100
Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives 99
The influence of auranofin, a clinically established antiarthritic gold drug, on bone metabolism: analysis of its effects on human multipotent adipose-derived stem cells, taken as a model 90
GOLD(III) COMPOUNDS AS ANTICANCER AGENTS: RELEVANCE OF GOLD-PROTEIN INTERACTIONS FOR THE MECHANISM OF ACTION 88
Antitumor gold(III) complexes 83
null 82
Antiplasmodial Effects of a few Selected Natural Flavonoids and their Modulation of Artemisinin Activity 81
ESI MS characterization of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes 79
Selected Cytotoxic Gold Compounds cause Significant Inhibition of 20S Proteasome Catalytic Activities 77
Proanthocyanidin glycosides from the leaves of Quercus ilex L. (Fagaceae) 77
Proteins as possible targets for antitumor metal complexes: biophysical studies of their interactions 73
Gold compounds: new anticancer drugs candidates. Studies of protein metalation processes 71
New uses for old drugs. auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications 69
Recent Trends in Antitumor Gold(III) Complexes: innovative cytotoxic metallodrugs for cancer treatment 68
Structure-function relationships within Keppler-type antitumor ruthenium(III) complexes: the case of 2-amino-thiazolium[(bis 2-aminothiazole) tetrachloro ruthenate(III)] 66
Gold(III) Compounds: antitumor metallodrugs with innovative mechanisms of action. 66
Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-imidazole dimethylsulfoxide-tetrachloro ruthenate with hen egg white lysozyme and horse heart cytochrome c. 66
null 66
Mechanistic studies on cytotoxic gold compounds 64
Reactions of cisplatin and cis-[PtI2(NH3)2] with molecular models of relevant protein sidechains: A comparative analysis 64
fac-Ru(CO)(3)(2+) selectively targets the histidine residues of the beta-amyloid peptide 1-28. Implications for new Alzheimer's disease treatments based on ruthenium complexes. 62
Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel “Rule-Breaker” Iodidoplatinum(II) Complex 61
New copper(II)/cyclic tetrapeptide system that easily oxidizes to copper(III) under atmospheric oxygen. 60
[Au2(phen2Me)2(μ-O)2](PF6)2, a Novel Dinuclear Gold(III)Complex Showing Excellent Antiproliferative Properties 59
Studies of cytotoxic gold compounds: interactions with model proteins and with the copper chaperone Atox-1 57
Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(II) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. 57
null 54
Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bs(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound. 54
Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. 53
null 51
New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. 50
null 47
Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability. 41
null 41
null 32
null 31
null 27
null 26
null 11
Totale 7.749
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.601
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.601
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020999 0 0 0 0 148 166 141 186 141 75 124 18
2020/2021868 77 72 75 82 30 111 42 74 72 114 33 86
2021/2022471 22 41 35 16 35 26 19 22 23 21 108 103
2022/20231.293 124 205 74 121 101 238 175 81 120 10 25 19
2023/2024376 27 39 69 22 16 26 29 75 15 11 44 3
2024/20251.874 80 288 203 468 835 0 0 0 0 0 0 0
Totale 7.749